Literature DB >> 21845421

Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.

Eileen M Boyle1, Franck Morschhauser.   

Abstract

Rituximab, a monoclonal antibody (mAb) directed against CD20, has changed practices in the treatment of patients with B-cell lymphoma. The large success of rituximab has contributed to validate immunotherapy with monoclonal antibodies as a valuable strategy in lymphoma. Recently, better-engineered anti-CD20-mAbs have been designed to improve efficacy and safety. Also, new antibodies targeting other lymphoma subtypes including T-cell lymphoma and Hodgkin's disease have been developed. Ongoing pharmacology development is concentrating on immuno-drug-conjugates combining the toxicity of chemotherapy, isotopes, or toxins with the specificity of mAbs. This article offers an overview on the development of new antibodies and immuno conjugates in lymphoma.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21845421     DOI： 10.1007/s11912-011-0190-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  47 in total

1.  Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.

Authors:  Lining Zhang; Qun Wang; Xiaoyan Wang; Peifang Ding; Jing Song; Chunhong Ma; Wensheng Sun
Journal:  Cell Mol Immunol       Date:  2004-02       Impact factor: 11.530

2.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

Authors:  Oliver W Press; Joseph M Unger; Rita M Braziel; David G Maloney; Thomas P Miller; Michael Leblanc; Richard I Fisher
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

3.  High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

Authors:  Franck Morschhauser; Françoise Kraeber-Bodéré; William A Wegener; Jean-Luc Harousseau; Marie-Odile Petillon; Damien Huglo; Lorenz H Trümper; Johannes Meller; Michael Pfreundschuh; Carl-Martin Kirsch; Ralph Naumann; Joachim Kropp; Heather Horne; Nick Teoh; Steven Le Gouill; Caroline Bodet-Milin; Jean-Francois Chatal; David M Goldenberg
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

4.  A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

Authors:  Carla Casulo; Julie M Vose; William Y Ho; Brad Kahl; Mark Brunvand; Andre Goy; Yvette Kasamon; Bruce Cheson; Jonathan W Friedberg
Journal:  Clin Immunol       Date:  2014-06-11       Impact factor: 3.969

5.  A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

Authors:  Ivana N M Micallef; Brad S Kahl; Matthew J Maurer; Ahmet Dogan; Stephen M Ansell; Joseph P Colgan; Susan Geyer; David J Inwards; William L White; Thomas M Habermann
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

6.  Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Authors:  John P Leonard; Morton Coleman; Jamie C Ketas; Amy Chadburn; Richard Furman; Michael W Schuster; Eric J Feldman; Michelle Ashe; Stephen J Schuster; William A Wegener; Hans J Hansen; Heather Ziccardi; Michael Eschenberg; Urte Gayko; Scott Z Fields; Alessandra Cesano; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Authors:  Gunilla Enblad; Hans Hagberg; Martin Erlanson; Jeanette Lundin; Anja Porwit MacDonald; Roland Repp; Johannes Schetelig; Gernot Seipelt; Anders Osterborg
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

8.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

Authors:  Andrea Gallamini; Francesco Zaja; Caterina Patti; Atto Billio; Maria Rosaria Specchia; Alessandra Tucci; Alessandro Levis; Annunziata Manna; Vicenzo Secondo; Luigi Rigacci; Antonello Pinto; Emilio Iannitto; Valerio Zoli; Pierfederico Torchio; Stefano Pileri; Corrado Tarella
Journal:  Blood       Date:  2007-06-20       Impact factor: 22.113

9.  A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Authors:  P L Zinzani; M Tani; S Fanti; V Stefoni; G Musuraca; P Castellucci; E Marchi; M Farsad; M Fina; C Pellegrini; L Alinari; E Derenzini; A de Vivo; F Bacci; S Pileri; M Baccarani
Journal:  Ann Oncol       Date:  2008-02-25       Impact factor: 32.976

10.  First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Authors:  Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
Journal:  Blood       Date:  2008-04-04       Impact factor: 22.113
View more
  2 in total

1.  Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab.

Authors:  Bryan A Garcia; Sarah Tinsley; Thomas Schellenberger; George C Bobustuc
Journal:  Med Oncol       Date:  2011-12-08       Impact factor: 3.064

2.  Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.

Authors:  Murat Elli; Sema Yilmaz; Ramazan Aydin; Sadriye Murat; Meltem Ceyhan Bilgici; Ayhan Dagdemir
Journal:  Mol Clin Oncol       Date:  2013-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.